TRANSDERMIS

GOAL

Evaluation of the efficacy of photobiomodulation (PBM) therapy in the prevention  of acute radiodermatitis in breast cancer patients

STUDY DESIGN

Placebo-controlled, randomized trial with breast cancer patients undergoing radiotherapy after a breast sparing surgery at the Jessa Hospital (NCT02443493) from April 2015 until June 2017

Control group (n=60)	Laser group (n=60)
Standard skin care	Standard skin care
Radiotherapy (standard regimen)	Radiotherapy (standard regimen)
Placebo treatment (2x/week, from start radiotherapy)	PBM (2x/week, from start radiotherapy)

STUDY RESULTS

PBM diminishes the severity of acute radiodermatitis during radiotherapy with 30% and improves the patient's quality of life

PUBLICATIONS

Robijns J, Censabella S, Claes S, Pannekoeke L, Bussé L, Colson D, Kaminski I, Bulens P, Maes A, Noé L, Brosens M, Timmermans A, Lambrichts I, Somers V, Mebis J. Prevention of acute radiodermatitis by photobiomodulation: A randomized, placebo-controlled trial in breast cancer patients (TRANSDERMIS trial). Lasers Surg Med. 2018. 50(7): p.763-771.
Impact factor 2018: 3.262

Robijns J, Censabella S, Claes S, Pannekoeke L, Bussé L, Colson D, Kaminski I, Lodewijckx J, Bulens P, Maes A, Noé L, Brosens M, Timmermans A, Lambrichts I, Somers V, Mebis J. Biophysical skin measurements to evaluate the effectiveness of photobiomodulation therapy in the prevention of acute radiation dermatitis in breast cancer patients. Support Care Cancer. 2019 Apr;27(4):1245-1254.
Impact factor 2018: 2.754

PARTNERS